KR20030030883A - Pharmaceutical composition for recovering from fatigue - Google Patents
Pharmaceutical composition for recovering from fatigue Download PDFInfo
- Publication number
- KR20030030883A KR20030030883A KR1020020060905A KR20020060905A KR20030030883A KR 20030030883 A KR20030030883 A KR 20030030883A KR 1020020060905 A KR1020020060905 A KR 1020020060905A KR 20020060905 A KR20020060905 A KR 20020060905A KR 20030030883 A KR20030030883 A KR 20030030883A
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- pharmaceutical composition
- fatigue
- weight
- fatigue recovery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Description
본 발명은 피로 회복 의약 조성물에 관한 것이다. 더욱 상세히는 피로 증상의 개선·회복을 목적으로 해 사용되는 피로 회복 의약 조성물에 관한 것이다.The present invention relates to a fatigue recovery pharmaceutical composition. More specifically, the present invention relates to a fatigue recovery pharmaceutical composition used for the purpose of improving and recovering from fatigue symptoms.
종래부터, 피로 증상의 개선·회복을 목적으로 각종 피로 회복 의약 조성물이 제공되고 있다. 그러나, 종래 제공되고 있는 피로 회복 의약 조성물은 피로 회복 작용이 충분하지 않거나, 장기간 복용하는 경우 안전성에 의문이 있는 것도 존재하고 있었다.Background Art Conventionally, various fatigue recovery pharmaceutical compositions have been provided for the purpose of improving and recovering from fatigue symptoms. However, the fatigue recovery pharmaceutical composition provided conventionally has not enough fatigue recovery effect, or there existed a question about safety when taking for a long time.
따라서, 본 발명의 목적은 보다 피로회복효과가 우수하고, 안전성이 높으며, 장기간에 걸쳐 복용할 수 있는 피로회복 의약 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a fatigue recovery pharmaceutical composition which is more excellent in fatigue recovery effect, has high safety, and can be taken for a long time.
본 발명자들은 상기 과제를 해결하기 위하여, 의약 성분의 배합에 대해서 예의 검토한 결과, 헤프로니케이트(hepronicate)와 비타민 B류를 조합하여 배합하면, 각각을 단독으로 사용했을 경우에 비해, 피로 회복효과가 비약적으로 향상하는 것을 발견하고, 본 발명을 완성하기에 이르렀다.MEANS TO SOLVE THE PROBLEM In order to solve the said subject, as a result of earnestly examining the compounding of a pharmaceutical component, when it mix | blends a combination of hepronicate and vitamin B, it is possible to recover from fatigue compared with the case where each is used alone. It has been found that the effect is greatly improved, and the present invention has been completed.
즉, 본 발명은 헤프로니케이트와 비타민 B류를 유효성분으로서 함유하는 것을 특징으로 하는 피로회복 의약 조성물을 제공하는 것이다.That is, the present invention is to provide a fatigue recovery pharmaceutical composition characterized in that it contains hepronicate and vitamin B as an active ingredient.
도 1은 시험예 1에서 행한 배 복근 전기 자극 유발관계 피로에 대한 피로 회복시험의 결과(배복근 피로계수)를 나타내는 도면이다.BRIEF DESCRIPTION OF THE DRAWINGS It is a figure which shows the result (abdominal muscle fatigue coefficient) of the fatigue recovery test with respect to fatigue of abdominal muscle electric stimulation-induced relationship performed in the test example 1.
본 발명의 피로회복 의약 조성물(이하, 「의약 조성물」이라고 한다)에 있어서, 사용되는 헤프로니케이트는 혈류개선 작용, 혈소판 응집 억제작용, 섬유소 용해작용 등의 약리효과를 가지는 말초혈관 확장제로서 알려져, 레이노병, 버저병, 폐색성 동맥경화증 등의 말초순환장해, 동창, 동상의 약제로서 종래부터 사용되고 있는 화합물이다.In the fatigue recovery pharmaceutical composition of the present invention (hereinafter referred to as "pharmaceutical composition"), the heproicate used is known as a peripheral vasodilator having pharmacological effects such as blood flow improvement, platelet aggregation inhibitory action, and fibrin lysis. It is a compound conventionally used as a medicine for peripheral circulation disorders, alumni, and frostbite, such as Raynaud's disease, Buzzer's disease, and obstructive atherosclerosis.
한편, 본 발명의 의약 조성물에 있어서 사용되는 비타민 B류로서는 비타민B1, B2, B5, B6, B12등을 들 수 있으며, 이 가운데 바람직한 것으로서는, 비타민 B1및 B6를 들 수 있다. 이 중, 비타민 B1은 종래부터 일반용 의약품으로서 신경통, 요통, 어깨 결림, 오십견 등의 근육통·관절통, 수족 저림, 변비, 안구 피로의여러 증상의 완화, 각기병이나, 육체 피로시, 임신· 수유기, 병중 병후의 체력 저하시에 이용되고 있는 화합물이다. 또한, 비타민 B6는 구각염, 입술염, 구내염, 설염, 습진, 피부염, 여드름의 여러 증상의 완화나, 임신·수유기, 병중 병후의 체력 저하시에 이용되고 있는 화합물이다.On the other hand, vitamin Bs used in the pharmaceutical composition of the present invention include vitamins B 1 , B 2 , B 5 , B 6 , B 12 , and the like, and vitamin B 1 and B 6 are preferred among them. Can be. Among these, vitamin B 1 is conventionally used as a general-purpose medicine, such as neuralgia, low back pain, stiff shoulders, muscle pain, joint pain, sputum, constipation, relief of various symptoms of ocular fatigue, each disease, physical fatigue, pregnancy and lactation, It is a compound used at the time of physical strength fall after illness. In addition, vitamin B 6 is a compound used for relief of various symptoms of stomatitis, lipitis, stomatitis, sulphitis, eczema, dermatitis and acne, and during pregnancy, lactation and illness.
본 발명의 의약 조성물에 있어서 사용되는 비타민 B1의 구체적인 예로서는, 염산티아민, 질산티아민, 질산비스티아민, 티아민디술파이드, 티아민디세틸 황산에스테르염, 염산 디세티아민, 염산 플루술티아민, 옥토티아민, 시코티아민, 비스이부티아민, 비스벤티아민, 플루술티아민, 프로술티아민, 벤포티아민 등을 들 수 있다. 이들은 일종 또는 2종이상을 혼합해 이용할 수 있다.Specific examples of vitamin B 1 used in the pharmaceutical composition of the present invention include thiamine hydrochloride, thiamine nitrate, bistiamine nitrate, thiamine disulfide, thiaminedecetyl sulfate ester salt, dicetiamine hydrochloride, flusulthiamine hydrochloride, octothiamine, and coco Thiamine, bisbutyamine, bisbenthiamine, flusulthiamine, prosulthiamine, benfothiamine and the like. These can be used 1 type or in mixture of 2 or more types.
또한, 본 발명의 의약 조성물에 있어서 사용되는 비타민 B6의 구체적인 예로서는 염산 피리독신, 인산피리독살 등을 들 수가 있다. 이들도 1종 또는 2종을 혼합해 이용할 수가 있다.Further, Specific examples of the vitamin B 6 is used in the pharmaceutical composition of the present invention can include pyridoxine hydrochloride, pyridoxal phosphate and the like. These can also be used 1 type or in mixture of 2 types.
본 발명의 의약 조성물의 헤프로니케이트와 비타민 B류의 배합 비율은 사용하는 비타민 B류에 의해 다르며, 예를 들면, 비타민 B류로서 비타민 B1을 사용하는 경우는, 통상, 헤프로니케이트 1중량부에 대해, 비타민 B1을 0.003∼10중량부 정도, 더욱 바람직하기로는, 0.5∼2중량부 정도이다. 한편, 비타민 B류로서 비타민 B5를 사용하는 경우의 배합비율은 통상 헤프로니케이트 1중량부에 대해 비타민 B5를 0.017∼10중량부 정도, 더욱 바람직하기로는 0.5∼2중량부 정도이다.The blending ratio of the hepronicate and vitamin B of the pharmaceutical composition of the present invention differs depending on the vitamin Bs used, and, for example, when vitamin B 1 is used as the vitamin Bs, heproicate is usually used. 1 weight part opted for, or so, more preferably from 0.003 to 10 parts by weight of the vitamin B 1 is a 0.5 to 2 parts by weight. On the other hand, the compounding ratio in the case of using vitamin B 5 as vitamin B is usually about 0.017 to 10 parts by weight, more preferably about 0.5 to 2 parts by weight of vitamin B 5 with respect to 1 part by weight of hepronicate.
또한, 본 발명의 의약 조성물에는, 필요에 따라 각종 약효성분을 배합할 수 있다. 이들의 약효성분의 예로서는, 비타민 C와 그의 유도체, 엽산, 비타민 D, K, H, A 및 레티노이드와 이들의 유도체 등의 비타민 B류이외의 비타민류를 들 수 있다. 또한, γ-오리자놀, L-염산 시스테인, L-시스테인, 우르소데스옥시콜산, 오로틴산, 글루클로노락톤, 글루크론산아미드, 콜로이드 로이틴 황산나트륨, 가공 마늘, 인삼, 이의인, 또는 칼슘, 철, 인, 마그네슘, 칼륨, 동, 요드, 망간, 셀렌, 아연, 크롬, 몰리부덴 등의 미네랄을 들 수 있다. 이들 약효성분은 본 발명의 효과를 해치지 않는 범위에서, 그의 1종 또는 2종이상을 배합할 수 있다.Moreover, various pharmaceutical ingredients can be mix | blended with the pharmaceutical composition of this invention as needed. Examples of these medicinal ingredients include vitamins other than vitamin B, such as vitamin C and its derivatives, folic acid, vitamins D, K, H, A and retinoids and derivatives thereof. In addition, γ-orizanol, L-cysteine hydrochloride, L-cysteine, urodesoxycholic acid, orotinic acid, gluclonolactone, glucronamide, colloidal leutin sulfate, processed garlic, ginseng, its phosphorus, or calcium, iron And minerals such as phosphorus, magnesium, potassium, copper, iodine, manganese, selenium, zinc, chromium and molybdenum. These drug active ingredients can be mix | blended 1 type, or 2 or more types in the range which does not impair the effect of this invention.
본 발명의 의약 조성물은 상기한 헤프로니케이트, 비타민 B류 및 필요에 따라 다른 약효성분을 배합하고, 통상의 방법에 따라 제재화함으로써 조제된다.The pharmaceutical composition of this invention is prepared by mix | blending said hepronicate, vitamin B, and other active ingredient as needed, and formulating it according to a conventional method.
이 의약 조성물의 조제에 있어서는, 필요에 따라 공지의 제제 첨가제를 사용할 수 있다. 이러한, 제제 첨가제의 예로서는, 안정(화)제, 계면활성제, 가소제, 활택화제, 활택제, 가용(화)제, 환원제, 완충제, 감미제, 기제, 흡착제, 교미제, 결합제, 현탁(화)제, 항산화제, 광택화제, 코팅제, 제피, 습윤제, 습윤 조정제, 충전제, 소포제, 청량화제, 착색제, 착향제, 향료, 당의제, 등장화제, 연화제, 유화제, 점조화제, 점조제, 발포제, pH 조정제, 희석제 및 부형제, 분산제, 붕괴제, 붕괴 보조제, 붕괴연장제, 방향제, 방습제, 방부제, 보존제, 용해제, 용해 보조제, 용제, 유동화제, 대전방지제, 증량제, 보습제, 부습제 등을 들 수가 있다.In preparation of this pharmaceutical composition, a well-known formulation additive can be used as needed. Examples of such formulation additives include stabilizers, surfactants, plasticizers, glidants, lubricants, solubilizers, reducing agents, buffers, sweeteners, bases, adsorbents, mating agents, binders, and suspending agents. , Antioxidants, brightening agents, coatings, coatings, wetting agents, wetting agents, fillers, antifoaming agents, cooling agents, colorants, flavoring agents, flavoring agents, dragees, isotonic agents, emollients, emulsifiers, viscous agents, viscous agents, foaming agents, pH adjusters And diluents and excipients, dispersants, disintegrating agents, disintegrating aids, disintegrating extenders, fragrances, desiccants, preservatives, preservatives, solubilizers, dissolution aids, solvents, glidants, antistatic agents, extenders, humectants, dehumidifying agents and the like.
또한, 본 발명 의약 조성물의 제형의 예로서는, 정제, 과립제, 세립제, 산제, 캅셀제, 연질 캅셀제, 환약, 현탁제, 유제, 내복액제, 시럽제, 드라이 시럽제등의 경구투여 형태의 고형, 반고형 및 액상의 제제를 들 수 있다. 또한, 필요에 따라, 마이크로캅셀, 나노캅셀, 마이크로스페아, 나노스페아 등의 미소립자로 한 후, 전술의 제제로 하여도 좋다.In addition, examples of the formulation of the pharmaceutical composition of the present invention include solid, semi-solid, and oral dosage forms such as tablets, granules, fine granules, powders, capsules, soft capsules, pills, suspensions, emulsions, oral solutions, syrups, and dry syrups. Liquid preparations are mentioned. Moreover, after making it into microparticles | fine-particles, such as a microcapsule, a nanocapsule, a micro spare, and a nano spare, as needed, you may make it the above-mentioned formulation.
[실시예]EXAMPLE
이하, 실시예 및 시험예를 들어 본 발명을 구체적으로 설명하나, 본 발명은 이들 실시예 등에 하등 제약되는 것은 아니다.Hereinafter, although an Example and a test example are given and this invention is demonstrated concretely, this invention is not restrict | limited at all by these Examples.
실시예 1Example 1
헤프로니케이트 1g, 비스티아민 1g 및 염산 피리독신 1g을 균일하게 혼합하여 산제로서 본 발명의 피로 회복 의약 조성물을 얻었다.1 g of hepronicate, 1 g of bistiamine and 1 g of pyridoxine hydrochloride were uniformly mixed to obtain a fatigue recovery pharmaceutical composition of the present invention as a powder.
비교예 1Comparative Example 1
비스티아민 1g 및 염산 피리독신 1g를 균일하게 혼합하여 비교예 1의 산제를 얻었다.1 g of bistiamine and 1 g of pyridoxine hydrochloride were uniformly mixed to obtain a powder of Comparative Example 1.
실시예 2Example 2
헤프로니케이트 1g, 염산 플루술티아민 1g 및 염산 피리독신 1g를 균일하게 혼합하여 산제로서 본 발명의 피로 회복 의약 조성물을 얻었다.1 g of hepronicate, 1 g of flusulthiamine hydrochloride, and 1 g of pyridoxine hydrochloride were uniformly mixed to obtain a fatigue recovery pharmaceutical composition of the present invention as a powder.
비교예 2Comparative Example 2
염산 플루술티아민 1g 및 염산 피리독신 1g를 균일하게 혼합하여 비교예 2의 산제를 얻었다.1 g of flusulthiamine hydrochloride and 1 g of pyridoxine hydrochloride were uniformly mixed to obtain a powder of Comparative Example 2.
시험예 1Test Example 1
배복근 전기 자극 유발관계 피로에 대한 피로회복 시험:Fatigue recovery test for fatigue
(1) 시험 방법(1) test method
피로회복 시험에는 18시간 절식한 수컷 Wistar계 랫트(5주령)를 1군 5마리로서 25마리 이용했다. 시험 약제에는 본 발명 실시예 1 및 2, 그리고 비교예 1 및 2에서 얻은 제제를 사용했다. 각 시험 약제는 0.5% CMC-Na에 현탁하고, 후술하는 4Hz의 자극을, 15분간 부여한 직후에 십이지장내 투여했다. 투여량은, 실시예 1 및 2는 15 mg/kg, 비교예 1 및 2는 10mg/kg로 하고, 대조에는 0.5% CMC-Na(5 ㎖/kg)를 동일하게 투여했다.In the fatigue recovery test, 25 male Wistar rats (5 weeks old), fasted for 18 hours, were used as five in one group. As the test medicament, the formulations obtained in Examples 1 and 2 of the present invention and Comparative Examples 1 and 2 were used. Each test agent was suspended in 0.5% CMC-Na and administered in the duodenum immediately after giving a stimulus of 4 Hz described below for 15 minutes. The dosage was 15 mg / kg in Examples 1 and 2, 10 mg / kg in Comparative Examples 1 and 2, and 0.5% CMC-Na (5 ml / kg) was similarly administered to the control.
시험은 우레탄 마취한 동물의 십이지장내에 캐뉼레를 삽입하고, 배 위치에 고정한 후, 오른쪽 뒷다리 배복근을 박리하고, 등척성 트랜스듀서(오리엔테크사 제)를 끼워 근육 수축을 기록함으로써 행했다.The test was performed by inserting a cannula into the duodenum of a urethane anesthetized animal, fixing it to the position of the stomach, peeling the right hind abdominal muscle, and recording a muscle contraction by inserting an isometric transducer (Orientech Co., Ltd.).
배복근의 피로회복 시험은 다음과 같이 행했다. 즉, 0.1Hz에서 전기 자극(자극폭: 1.5 msec, 역치전압)하고, 수축이 안정된 후, 4Hz로 15분간 자극하고, 근육피로를 유발시켰다. 각 랫트에 소정의 시험약제를 투여한 후, 28분간 자극을 쉬고, 그 후에 4Hz자극을 2분간 가하고, 이후, 30분마다 같은 자극을 가다. 2분간 자극에서 얻어진 최대 수축력과 근육피로 유발시의 최대 수축력으로부터 다음 식에 의해 변화율을 산출하여 배복근 피로계수(%)로 했다.Bae abdominal muscle fatigue test was performed as follows. That is, the electrical stimulation (stimulation width: 1.5 msec, threshold voltage) at 0.1Hz, the contraction was stabilized, then stimulated for 15 minutes at 4Hz, causing muscle fatigue. After administering the test drug to each rat, the stimulus was rested for 28 minutes, after which the 4 Hz stimulus was added for 2 minutes, and then the same stimulus was applied every 30 minutes. From the maximum contraction force obtained by stimulation for 2 minutes and the maximum contraction force at the time of inducing muscle fatigue, the rate of change was calculated according to the following equation, and the abdominal muscle fatigue coefficient (%) was calculated.
(결과)(result)
시험 약제 투여 90 분 후의 배복근 피로계수를 도 1에 나타냈다. 도 1로부터 명백한 바와 같이, 실시예 1과 비교예 1, 실시예 2와 비교예 2를 비교하면, 본 발명의 피로회복 의약조성물 투여군은 배복근 피로계수가 비교예에 비해 작고, 비타민 B1및 비타민 B6에 헤프로니케이트를 배합함으로써 피로회복효과가 증강되고 있음이 확인되었다.The abdominal muscle fatigue coefficient 90 minutes after test drug administration is shown in FIG. 1. As is apparent from FIG. 1, when comparing Example 1 with Comparative Example 1, Example 2 and Comparative Example 2, the fatigue recovery pharmaceutical composition-administered group of the present invention has a smaller abdominal muscle fatigue coefficient than the comparative example, and vitamin B 1 and It was confirmed that the fatigue recovery effect was enhanced by incorporating hepronicate into vitamin B 6 .
실시예 3Example 3
헤프로니케이트 100g, 염산 플루술티아민 100g, 염산 피리독신 100g 및 옥수수 전분 100g을 균일하게 혼합한 후, 경질 캅셀 1개에 대해 200mg이 되도록 충전하여 경질 캅셀제로서 본 발명의 피로 회복 의약 조성물을 얻었다.After uniformly mixing 100 g of hepronicate, 100 g of flusulthiamine hydrochloride, 100 g of pyridoxine hydrochloride, and 100 g of corn starch, the mixture was filled up to 200 mg with respect to one hard capsule to obtain a fatigue recovery pharmaceutical composition of the present invention as a hard capsule.
실시예 4Example 4
헤프로니케이트 500g, 질산티아민 500g, 염산 피리독신 500g, 락토오즈 740g 및 결정 셀루로오즈 740g를 균일하게 혼합하고, 20호 시이브로 체절한 후, 다시 탈크 15g, 스테아린산마그네슘 5g을 혼합하여 타정용 분말을 얻었다. 직경 9.5mm의타정기를 이용하여 1정당 300mg이 되도록 타정하여 정제로서 본 발명의 피로 회복 의약 조성물을 얻었다.500 g of hepronicate, 500 g of thiamine nitrate, 500 g of pyridoxine hydrochloride, 740 g of lactose and 740 g of crystalline cellulose are mixed uniformly, and then sieved with No. 20 sieve, and then 15 g of talc and 5 g of magnesium stearate are mixed for tableting powder. Got. The tablet was tableted to 300 mg per tablet using a tableting machine having a diameter of 9.5 mm to obtain the fatigue recovery pharmaceutical composition of the present invention as a tablet.
실시예 5Example 5
헤프로니케이트 200g, 비스티아민 200g, 염산 피리독신 200g 및 대두유 1200g을 통상의 방법에 의해 교반 혼합했다. 얻어진 조성물을 소프트 캅셀 연속 자동 제조기에 공급하여 내용물 300 mg의 소프트 캅셀로서 본 발명의 피로 회복 의약 조성물을 얻었다.200 g of hepronicate, 200 g of bistiamine, 200 g of pyridoxine hydrochloride and 1200 g of soybean oil were stirred and mixed by a conventional method. The obtained composition was fed to a soft capsule continuous automatic maker to obtain a fatigue recovery pharmaceutical composition of the present invention as a soft capsule having a content of 300 mg.
본 발명의 피로 회복 의약 조성물은 헤프로니케이트 및 비타민 B류를 조합하고, 유효성분으로서 함유함으로써 이들을 단독으로 배합했을 경우에 비하여 피로회복효과를 비약적으로 향상시킬 수 있는 것이다.The fatigue recovery pharmaceutical composition of this invention can improve a fatigue recovery effect remarkably compared with the case where it is mix | blended alone by combining hepronicate and vitamin B, and containing them as an active ingredient.
Claims (7)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001315820A JP2003119139A (en) | 2001-10-12 | 2001-10-12 | Fatigue relieving pharmaceutical composition |
| JPJP-P-2001-00315820 | 2001-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030030883A true KR20030030883A (en) | 2003-04-18 |
Family
ID=19133936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020020060905A KR20030030883A (en) | 2001-10-12 | 2002-10-07 | Pharmaceutical composition for recovering from fatigue |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2003119139A (en) |
| KR (1) | KR20030030883A (en) |
| CN (1) | CN1244326C (en) |
| HK (1) | HK1054694A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101299885B1 (en) * | 2005-05-27 | 2013-08-23 | 코와 가부시키가이샤 | Pharmaceutical preparation for recovery from fatigue |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01308232A (en) * | 1988-06-03 | 1989-12-12 | Takeda Chem Ind Ltd | Solid drug and production thereof |
| JPH08283148A (en) * | 1995-02-17 | 1996-10-29 | Takeda Chem Ind Ltd | Depressive symptom improver |
| JPH10287560A (en) * | 1997-04-11 | 1998-10-27 | Taisho Pharmaceut Co Ltd | Pharmaceutical composition |
| KR20010024462A (en) * | 1997-10-08 | 2001-03-26 | 세로톤, 인코포레이티드 | Serotonin containing formulation for oral administration and method of use |
| KR20010055274A (en) * | 1999-12-10 | 2001-07-04 | 김재수 | Health augmentation food for the anti fatigue |
-
2001
- 2001-10-12 JP JP2001315820A patent/JP2003119139A/en active Pending
-
2002
- 2002-09-29 CN CNB021439818A patent/CN1244326C/en not_active Expired - Fee Related
- 2002-10-07 KR KR1020020060905A patent/KR20030030883A/en not_active Application Discontinuation
-
2003
- 2003-09-30 HK HK03107056A patent/HK1054694A1/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01308232A (en) * | 1988-06-03 | 1989-12-12 | Takeda Chem Ind Ltd | Solid drug and production thereof |
| JPH08283148A (en) * | 1995-02-17 | 1996-10-29 | Takeda Chem Ind Ltd | Depressive symptom improver |
| JPH10287560A (en) * | 1997-04-11 | 1998-10-27 | Taisho Pharmaceut Co Ltd | Pharmaceutical composition |
| KR20010024462A (en) * | 1997-10-08 | 2001-03-26 | 세로톤, 인코포레이티드 | Serotonin containing formulation for oral administration and method of use |
| KR20010055274A (en) * | 1999-12-10 | 2001-07-04 | 김재수 | Health augmentation food for the anti fatigue |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1054694A1 (en) | 2003-12-12 |
| JP2003119139A (en) | 2003-04-23 |
| CN1411810A (en) | 2003-04-23 |
| CN1244326C (en) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1296671B1 (en) | Gabapentin analogues for sleep disorders | |
| US4351831A (en) | Process and composition for treating disorders by administering isoxsurpine and choline | |
| JPH05320052A (en) | Nucleic acid ingredient composition | |
| EP0105924B1 (en) | Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof | |
| KR20020031331A (en) | Methods of Treatment of Mitochondrial Disorders | |
| US4636494A (en) | Process and composition for treating disorders by administering amphetamine and choline | |
| JP3514955B2 (en) | Calcium absorption enhancing composition | |
| JPH06502148A (en) | antidepressants | |
| EP1088551A1 (en) | Medicinal compositions for treating evacuatory insufficiency | |
| JP4129566B2 (en) | Liver fat accumulation inhibiting composition and food additive for liver fat accumulation inhibiting | |
| JP5114399B2 (en) | Drugs for fatigue prevention and / or recovery | |
| US4346085A (en) | Process and composition for treating disorders by administering amphetamine and choline | |
| JP2000515559A (en) | How to lose weight | |
| US4346084A (en) | Process and composition for treating disorders by administering lithium and choline | |
| KR20030030883A (en) | Pharmaceutical composition for recovering from fatigue | |
| WO2006064744A1 (en) | Medicinal composition for treating diabetes | |
| JP2698865B2 (en) | Agent for myotonic dystrophy | |
| JPS5869813A (en) | Serum lipid depressant | |
| JP2710633B2 (en) | Heart disease treatment | |
| JPH0667833B2 (en) | Enteral nutrition | |
| WO1998000148A1 (en) | Drug preparations, containing creatine with at least one salt of calcium, magnesium, manganese or zinc | |
| EP0614662A1 (en) | Use of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid for the treatment of leukaemia | |
| US3639597A (en) | Pharmaceutical compositions containing cholanic acid conjugates | |
| JPH0136804B2 (en) | ||
| US7625916B2 (en) | Medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |